PURPOSE: Recently, @entity1749 has been used to treat @entity465 ( @entity465 ) refractory to conventional treatment such as plasmapheresis, intravenous immunoglobulin, and rituximab. The authors aimed to describe their experiences when @entity1749 was used to treat refractory @entity465 . MATERIALS AND METHODS: Eleven refractory @entity465 episodes treated with @entity1749 were included in this study. The @entity1 received one or two cycles of @entity1749 (1.3 mg/m  ) on days 1, 4, 8, and 11. RESULTS: @entity1749 effectively reduced antibodies against various targets, including human leukocyte antigen (HLA) class I and II, @entity7743 . Antibodies were depleted or reduced significantly in eight @entity465 episodes. Overall, there was a significant improvement in the mean estimated glomerular filtration rate (eGFR) at 3 months after therapy (36.91  22.15 mL/ @entity1009 .73 m  ) versus eGFR at time of @entity465 diagnosis (17.00  9.25 mL/ @entity1009 .73 m  ; p=0.007). All six early-onset @entity465 episodes (within 6 months post-transplantation) showed full recovery of allograft function. Additionally, three of the five late-onset @entity465 episodes (>6 months post-transplantation) showed improved allograft function. CONCLUSION: Anti-humoral treatment based on @entity1749 might be an effective strategy against refractory @entity465 caused by various types of antibodies. Notably, this treatment could be more effective in early-onset @entity465 than in late-onset @entity465 .

The Effect of XXXX on Antibody-Mediated Rejection after Kidney Transplantation.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1009 :: ('966', 'Gene') :: ['min/1'] @entity465 :: ('MESH:D007153', 'Disease') :: ['AMR', 'antibody-mediated rejection'] @entity1749 :: ('MESH:C400082', 'Chemical') :: ['bortezomib', 'Bortezomib'] @entity7743 :: ('185', 'Gene') :: ['ABO blood group antigen, and angiotensin II type 1 receptor']
@entity1749 :: (MESH:C400082,Chemical) :: ['Bortezomib']
